Biogen Will Assert New Tecfidera Patent Amid Hexal Germany Launch
Three Dimethyl Fumarate MAAs Were Approved By The EC In May
Biogen has conceded that generics to its Tecfidera treatment for relapsing remitting multiple sclerosis may launch “at risk” in the EU, after the US-based player was recently granted further patent protection until 2028.
